KOL Identification

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

A large pharmaceutical company engaged DeciBio to evaluate strategies for an internal build of a lab to support clinical and commercial opportunities in oncology

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A diagnostics company requested DeciBio to help an advisory board (ad board) to understand how to position its relatively new somatic oncology genomics profiling product in an already competitive market

A multi-billion dollar life science company needed pre diligence on a potential acquisition target

A UK-based life science services provider was interested in learning more about the value and market landscape for synthetic mRNA production to inform a potential acquisition strategy